HAVN Life Sciences Inc.

CNSX: HAVN


Canadian symbol: HAVN.CN
US symbol: HAVLF

Currency in CAD

Valuation Measures

Market Cap (intraday) 568.35M
Enterprise Value 354.91M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)4.34
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 7N/A

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 322.95%
S&P500 52-Week Change 343.61%
52 Week High 31.5200
52 Week Low 30.5000
50-Day Moving Average 30.7137
200-Day Moving Average 30.8651

Share Statistics

Avg Vol (3 month) 3285.77k
Avg Vol (10 day) 3161.55k
Shares Outstanding 589.94M
Implied Shares Outstanding 6N/A
Float 83.23M
% Held by Insiders 11.09%
% Held by Institutions 11.97%
Shares Short (Apr. 14, 2021) 485.96k
Short Ratio (Apr. 14, 2021) 40.35
Short % of Float (Apr. 14, 2021) 4N/A
Short % of Shares Outstanding (Apr. 14, 2021) 40.10%
Shares Short (prior month Mar. 14, 2021) 4148.24k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 4N/A
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Apr. 29, 2020
Most Recent Quarter (mrq)Jan. 30, 2021

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)N/A
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA N/A
Net Income Avi to Common (ttm)-486.91k
Diluted EPS (ttm)-0.1560
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)13.34M
Total Cash Per Share (mrq)0.15
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)47.25
Book Value Per Share (mrq)0.17

Cash Flow Statement

Operating Cash Flow (ttm)-900.18k
Levered Free Cash Flow (ttm)N/A

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Psychedelics News and Psilocybin Investing

Real-time news from hundreds of sources. Never miss the news that matters the most.




Company News Date
HAVN.CN
HAVN Life Sciences
1 day ago
HAVN.CN
HAVN Life Sciences
3 days ago
HAVN.CN
HAVN Life Sciences
3 weeks ago
HAVN.CN
HAVN Life Sciences
3 weeks ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
1.09%% of Shares Held by All Insider
1.97%% of Shares Held by Institutions
1.99%% of Float Held by Institutions
3Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by HAVN Life Sciences Inc.


Havn Life Sciences Enters Definitive Agreement to Acquire Strategic Manufacturing & Packaging Facility for its Retail Division

The acquisition is intended to vertically integrate the Company's retail manufacturing capabilities to support the growth of its nutraceutical division and deliver unique products to consumersVANCOUVER, BC / ACCESSWIRE / January 26, 2021 / Havn Life Sciences Inc. (CNSX:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), a biote... Read More...

Havn Life Sciences and Nesters Market, a Leading Canadian Retailer of Natural Health and Wellness Products, Announce an Authorized Products Listing

Nesters Market retail chain, will list and promote the full range of Havn Life's natural health supplements across its stores in British Columbia in Q1 2021VANCOUVER, BC / ACCESSWIRE / December 22, 2020 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of... Read More...

Havn Life Sciences Files Preliminary Prospectus in Connection with Bought Deal Equity Financing

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATESVANCOUVER, BC / ACCESSWIRE / December 18, 2020 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life") is pleased to announce, further to its previously announced offering (the "Offering") on December 15, 2020, that it has filed a pre... Read More...

Havn Life Sciences Hits Major Milestone with Research Partner, Complex Biotech Discovery Ventures

Havn Research signs contract with CBDV, located at The University of British Columbia's Vancouver campus, to begin Health Canada approved research to analyze psilocybin under Havn Life's Section 56 exemption.The results of the analysis will allow Havn Life to begin the development of a library of psilocybin compounds.VANCOUVER, BC / ACCES... Read More...

Havn Life Sciences announces increase in Bought Deal Financing to $10 Million

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, Dec. 15, 2020 -- Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”) is pleased to announce that it has entered into an amended agreement with Eight Capital, pursuant to which Eight Capital has now ... Read More...

Havn Life Sciences Undertakes One of the First Preclinical Studies on Psilocybin and the Immune System

This is one of the first studies to examine how psilocybin affects the immune system and is a required step to file an application with the Food and Drug Administration (FDA), for a Phase 1 clinical study in humansVANCOUVER, BC / ACCESSWIRE / December 14, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), ... Read More...

Havn Life Sciences to Supply Psychedelic Compounds to Clinical Studies Focused on Veterans and PTSD

Havn Life will collaborate on future clinical studies with Heroic Hearts Project to investigate effects of low-dosage psychoactive compounds on veterans the post-traumatic stress disorder (PTSD). VANCOUVER, BC / ACCESSWIRE / December 8, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), a Canadian biotechn... Read More...

Havn Life Sciences Partners With Veterans Mental Health Non-Profit, Westwood Institute

Westwood Institute Founder, Dr. Marvin Westwood Will Work With Havn Life's Research Team to Develop Best Practices for Combining Therapy and Psychedelic Interventions for VeteransVANCOUVER, BC / ACCESSWIRE / December 3, 2020 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on un... Read More...

Havn Life Attracts International Drug Science and Policy Expert, Joins UK Policy Reform Group

Havn Life Has Joined the UK-Based Conservative Drug Policy Reform Group (CDPRG), Group Organized to Benefit Drug Policy-MakingThe Havn Life Advisory Board Adds Mr. King, a Vocal Advocate for Drug Policy Reform and ResearchVANCOUVER, BC / ACCESSWIRE / December 1, 2020 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Li... Read More...

Havn Life Sciences to Support the First Modern Psilocybin Depression Study in Germany With MIND Foundation

The research will be led by Prof. Dr. Gerhard Gründer, the only confirmed scientist developing a study to work with psychedelics in Germany since the 1970sVANCOUVER, BC / ACCESSWIRE / October 30, 2020 / Havn Life Sciences Inc. (CNSX:HAVN)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential... Read More...

Havn Life Sciences Earns Health Canada Approval for Natural Health Product Formulations

The initial six approved formulations were developed to enhance human performance and cognitive healthVANCOUVER, BC / ACCESSWIRE / October 26, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research and developing stan... Read More...

Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds

Expanding research and development of naturally-derived psilocybin for future FDA IND-enabling and clinical studiesTORONTO, Oct. 20, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disor... Read More...

Havn Life Sciences Announces Appointment of Dennis Staudt to the Board of Directors & Senior Management Reorganization

VANCOUVER, BC / ACCESSWIRE / October 19, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), is pleased to announce that Mr. Dennis Staudt has joined the Company's Board of Directors. Mr. Staudt has over 35 years' experience providing sophisticated business advice, having spent most of his career with Pric... Read More...

Havn Life Sciences Announces Appointments of Vic Neufeld as Chairman and Rick Brar as Vice Chairman of the Board of Directors, Respectively, and the Acceleration of Warrants

VANCOUVER, BC / ACCESSWIRE / October 5, 2020 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life") is pleased to announce that Mr. Vic Neufeld has been appointed as the Chairman of the Board of Directors of the Company (the "Board"). Mr. Neufeld brings a wealth of knowledge and experience in the Natural Health Food ... Read More...

Havn Life Sciences Granted Section 56 Exemption to Begin Scientific Work With Psilocybin

Havn Life will develop methods for safe, standardized, quality- controlled production of medical compounds extracted from the Psilocybe spp. mushroomVANCOUVER, BC / ACCESSWIRE / September 10, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidenc... Read More...
Coming Soon.

Delayed data (1h)


Share this page